Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression
暂无分享,去创建一个
Krzysztof Goryca | Tymon Rubel | Jerzy Ostrowski | Marcin Polkowski | Lucjan S Wyrwicz | M. Skrzypczak | J. Ostrowski | P. Rutkowski | K. Kokoszyńska | L. Wyrwicz | M. Pólkowski | A. Paziewska | K. Goryca | T. Rubel | D. Jarosz | Z. Nowecki | W. Ruka | Agnieszka Paziewska | Magdalena Skrzypczak | Katarzyna Kokoszyñska | Piotr Rutkowski | Zbigniew I Nowecki | Anna Jerzak Vel Dobosz | Dorota Jarosz | Wlodzimierz Ruka | A. Dobosz
[1] J. Schlessinger,et al. Signaling by Receptor Tyrosine Kinases , 1993 .
[2] D. Longo,et al. JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. , 1996, Blood.
[3] F. McCormick,et al. Regulation of Epidermal Growth Factor Receptor Signaling by Phosphorylation of the Ras Exchange Factor hSOS1 (*) , 1996, The Journal of Biological Chemistry.
[4] S. Ward,et al. Development and plasticity of interstitial cells of Cajal , 1999, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[5] Dipanwita Roy Chowdhury,et al. Human protein reference database as a discovery resource for proteomics , 2004, Nucleic Acids Res..
[6] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[7] J. Lasota,et al. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). , 2006, Seminars in diagnostic pathology.
[8] W. R. Burack,et al. The activating dual phosphorylation of MAPK by MEK is nonprocessive. , 1997, Biochemistry.
[9] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[10] J. Reguła,et al. Molecular defense mechanisms of Barrett’s metaplasia estimated by an integrative genomics , 2007, Journal of Molecular Medicine.
[11] S. Hirota,et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.
[12] A. Bernstein,et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. , 1989, Genes & development.
[13] W. H. Kim,et al. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining , 2007, Journal of Clinical Pathology.
[14] P. Besmer. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. , 1991, Current opinion in cell biology.
[15] M. Reyland. Protein kinase C isoforms: Multi-functional regulators of cell life and death. , 2009, Frontiers in bioscience.
[16] John E. Murphy,et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.
[17] N. Anderson,et al. The isoform-specific regulation of apoptosis by protein kinase C , 2003, Cellular and Molecular Life Sciences CMLS.
[18] J. Pfeiffer,et al. Wortmannin-sensitive phosphorylation, translocation, and activation of PLCgamma1, but not PLCgamma2, in antigen-stimulated RBL-2H3 mast cells. , 1998, Molecular biology of the cell.
[19] P. Besmer,et al. Kit signaling through PI 3‐kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation , 1998, The EMBO journal.
[20] J. Fletcher,et al. Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Tina Hernandez-Boussard,et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles , 2004, Oncogene.
[22] Hoguen Kim,et al. Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations , 2006, Proteomics.
[23] Don Gilbert,et al. Biomolecular Interaction Network Database , 2005, Briefings Bioinform..
[24] E. Liu,et al. Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors , 2005, Oncogene.
[25] Mike Tyers,et al. BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..
[26] P. Nyckowski,et al. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. , 2007, Medical science monitor : international medical journal of experimental and clinical research.
[27] P. Thall,et al. Association of Intratumoral Vascular Endothelial Growth Factor Expression and Clinical Outcome for Patients with Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate , 2007, Clinical Cancer Research.
[28] D. Fabbro,et al. Classical PKC isoforms in cancer. , 2007, Pharmacological research.
[29] S. Steigen,et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors , 2007, Laboratory Investigation.
[30] L. Koniaris,et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. , 2006, Journal of the American College of Surgeons.
[31] F. Galibert,et al. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains , 1995, Journal of Molecular Evolution.
[32] A. Mui,et al. The role of STATs in proliferation, differentiation, and apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.
[33] J. Lasota,et al. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.
[34] P. Dentelli,et al. STAT Protein Recruitment and Activation in c-Kit Deletion Mutants* , 1999, Journal of Biological Chemistry.
[35] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[36] A. Ullrich,et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.
[37] I. Kerr,et al. Jaks and Stats in signaling by the cytokine receptor superfamily. , 1995, Trends in genetics : TIG.
[38] L. Kindblom,et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.
[39] H. El‐Serag,et al. The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000 , 2005, The American Journal of Gastroenterology.
[40] Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours , 2007, British Journal of Cancer.
[41] J. Pfeiffer,et al. Wortmannin-Sensitive Phosphorylation, Translocation, and Activation of PLCγ1, but Not PLCγ2, in Antigen-stimulated RBL-2H3 Mast Cells , 1998 .
[42] J. Darnell,et al. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.